Genetic polymorphism of matrix metalloproteinases in breast cancer

Neoplasma

Volumn 59, Issue 3, 2012, Pages 237-247

  Wieczorek, E ^a   Reszka, E ^a   Gromadzinska, J ^a   Wasowicz, W ^a  

^a NOFER INSTITUTE OF OCCUPATIONAL MEDICINE   (Poland)

Author keywords

Breast cancer; Genetic polymorphism; Matrix metalloproteinases

Indexed keywords

COLLAGENASE 3; ESTROGEN RECEPTOR; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 21; NEUTROPHIL COLLAGENASE; STROMELYSIN; UNCLASSIFIED DRUG;

ALLELE; ANGIOGENESIS; BREAST CANCER; CANCER GROWTH; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; EXTRACELLULAR MATRIX; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENOTYPE; HUMAN; LYMPH NODE METASTASIS; META ANALYSIS (TOPIC); NONHUMAN; OVERALL SURVIVAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION; BREAST TUMOR; ENZYMOLOGY; FEMALE; GENETICS; PROGNOSIS;

BREAST NEOPLASMS; FEMALE; HUMANS; MATRIX METALLOPROTEINASES; POLYMORPHISM, GENETIC; PROGNOSIS;

EID: 84863823541     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2012_031     Document Type: Review

References (63)

1. JEMAL A, BRAY F, CENTER MM, FERLAY J, WARD E et al. Global Cancer Statistics. CA Cancer J Clin 2011;61:69-90. http://dx.doi.org/10.3322/caac.20107
2. KELSEY JL Breast-cancer epidemiology-summary and future-directions. Epidemiol Rev 1993; 15: 256-263.
3. ANTONIOU AC, PHAROAH PDP, MCMULLAN G, DAY NE, PONDER BAJ et al. Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet Epidemiol 2001; 21: 1-18. http://dx.doi.org/10.1002/gepi.1014
4. GROSS J, LAPIERE CM Collagenolytic activity in amphibian tissues-a tissue culture assay. Proc Natl Acad Sci U S A 1962; 48: 1014-1022. http://dx.doi.org/10.1073/pnas.48.6.1014
5. DEJONCKHEERE E, VANDENBROUCKE RE, LIBERT C Matrix metalloproteinase8 has a central role in inflammatory disorders and cancer progression. Cytokine Growth Factor Rev 2011; 22: 73-81. http://dx.doi.org/10.1016/j.cytogfr.2011.02.002
6. VISSE R, NAGASE H Matrix metalloproteinases and tissue inhibitors of metalloproteinases-Structure, function, and biochemistry. Circ Res 2003; 92: 827-39. http://dx.doi.org/10.1161/01.RES.0000070112.80711.3D
7. OVERALL CM Molecular determinants of metalloproteinase substrate specificity-Matrix metalloproteinase substrate binding domains, modules, and exosites. Mol Biotechnol 2002; 22: 51-86. http://dx.doi.org/10.1385/MB:22:1:051
8. NABESHIMA K, INOUE T, SHIMAO Y, SAMESHIMA T Matrix metalloproteinases in tumor invasion: Role for cell migration. Pathol Int 2002; 52: 255-264. http://dx.doi.org/10.1046/j.1440-1827.2002.01343.x
9. NAGASE H, WOESSNER JF Matrix metalloproteinases. J Biol Chem 1999; 274: 21491-21494. http://dx.doi.org/10.1074/jbc.274.31.21491
10. NGUYEN M, ARKELL J, JACKSON CJ Human endothelial gelatinases and angiogenesis. Int J Biochem Cell Biol 2001; 33: 960-970. http://dx.doi.org/10.1016/S1357-2725(01)00007-3
11. GIALELI C, THEOCHARIS AD, KARAMANOS NK Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 2011; 278: 16-27. http://dx.doi.org/10.1111/j.1742-4658.2010.07919.x
12. RADISKY ES, RADISKY DC Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia 2010; 15: 201-212 http://dx.doi.org/10.1007/s10911-010-9177-x
13. EGEBLAD M, WERB Z New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161-174. http://dx.doi.org/10.1038/nrc745
14. CARGILL M, ALTSHULER D, IRELAND J, SKLAR P, ARDLIE K et al. Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet 1999; 22: 231-238. http://dx.doi.org/10.1038/10290
15. GIBBS RA, BELMONT JW, HARDENBOL P, WILLIS TD, YU FL et al. The International HapMap Project. Nature 2003; 426: 789-796. http://dx.doi.org/10.1038/nature02168
16. CARLSON CS, EBERLE MA, KRUGLYAK L, NICKERSON DA Mapping complex disease loci in whole-genome association studies. Nature 2004; 429: 446-452. http://dx.doi.org/10.1038/nature02623
17. BALASUBRAMANIAN SP, BROWN NJ, REED MWR Role of genetic polymorphisms in tumour angiogenesis. Br J Cancer 2002; 87: 1057-1065. http://dx.doi.org/10.1038/sj.bjc.6600625
18. YAN CH, BOYD DD Regulation of matrix metalloproteinase gene expression. J Cell Physiol 2007; 211: 19-26. http://dx.doi.org/10.1002/jcp.20948
19. YE S Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol 2000; 19: 623-629. http://dx.doi.org/10.1016/S0945-053X(00)00102-5
20. DUFFY MJ, MAGUIRE TM, HILL A, MCDERMOTT E, O'HIGGINS N Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2000;2:252-257. http://dx.doi.org/10.1186/bcr65
21. HOLLIDAY DL, BROUILETTE KT, MARKERT A, GORDON LA, JONES JL Novel multicellular organotypic models of normal and malignant breast: tools for dissecting the role of the microenvironment in breast cancer progression. Breast Cancer Res 2009; 11: 1. http://dx.doi.org/10.1186/bcr2218
22. FANG SM, JIN X, WANG R, LI Y, GUO W et al. Polymorphisms in the MMP1 and MMP3 promoter and non-small cell lung carcinoma in North China. Carcinogenesis 2005; 26: 481-486.
23. MATSUMURA S, OUE N, NAKAYAMA H, KITADAI Y, YOSHIDA K et al. A single nucleotide polymorphism in the MMP-9 promoter affects tumor progression and invasive phenotype of gastric cancer. J Cancer Res Clin Oncol 2005;131:19-25. http://dx.doi.org/10.1007/s00432-004-0621-4
24. ECK SM, HOOPES PJ, PETRELLA BL, COON CI, BRINCKERHOFF CE Matrix metalloproteinase-1 promotes breast cancer angiogenesis and osteolysis in a novel in vivo model. Breast Cancer Res Treat 2009; 116: 79-90. http://dx.doi.org/10.1007/s10549-008-0085-3
25. LOO WTY, CHEUNG MNB, CHOW LWC Production of matrix metalloproteinases in specific subpopulations of human-patient breast cancer invading in three dimensional culture system. Life Sci 2004; 76: 743-752. http://dx.doi.org/10.1016/j.lfs.2004.06.027
26. PARK YH, JUNG HH, AHN JS, IM YH Ets-1 upregulates HER2-induced MMP-1 expression in breast cancer cells. Biochem Biophys Res Commun 2008; 377: 389-394. http://dx.doi.org/10.1016/j.bbrc.2008.09.135
27. RUTTER JL, MITCHELL TI, BUTTICE G, MEYERS J, GUSELLA JF et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res 1998; 58: 5321-5325.
28. TOWER GB, COON CC, BENBOW U, VINCENTI MP, BRINCKERHOFF CE Erk 1/2 differentially regulates the expression from the 1G/2G single nucleotide polymorphism in the MMP-1 promoter in melanoma cells. Biochim Biophys Acta 2002; 1586: 265-274.
29. BIONDI ML, TURRI O, LEVITI S, SEMINATI R, CECCHINI F et al. MMP1 and MMP3 polymorphisms in promoter regions and cancer. Clin Chem 2000; 46: 2023-2024.
30. LEI HX, HEMMINKI K, ALTIERI A, JOHANSSON R, ENQUIST K et al. Promoter polymorphisms in matrix metalloproteinases and their inhibitors: few associations with breast cancer susceptibility and progression. Breast Cancer Res Treat 2007; 103: 61-69. http://dx.doi.org/10.1007/s10549-006-9345-2
31. BEEGHLY-FADIEL A, CAI QY, LU W, LONG JR, GAO YT et al. No Association between Matrix Metalloproteinase-1 or Matrix Metalloproteinase-3 Polymorphisms and Breast Cancer Susceptibility: A Report from the Shanghai Breast Cancer Study. Cancer Epidemiol Biomarkers Prev 2009; 18: 1324-1327. http://dx.doi.org/10.1158/1055-9965.EPI-09-0046
32. GHILARDI G, BIONDI ML, CAPUTO M, LEVITI S, DEMONTI M et al. A single nucleotide polymorphism in the matrix metalloproteinase-3 promoter enhances breast cancer susceptibility. Clin Cancer Res 2002; 8: 3820-3823.
33. PRZYBYLOWSKA K, ZIELINSKA J, ZADROZNY M, KRAWCZYK T, KULIG A et al. An association between the matrix metalloproteinase 1 promoter gene polymorphism and lymphnode metastasis in breast cancer. J Exp Clin Cancer Res 2004; 23: 121-125.
34. PRZYBYLOWSKA K, KLUCZNA A, ZADROZNY M, KRAWCZYK T, KULIG A et al. Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancer. Breast Cancer Res Treat 2006; 95: 65-72. http://dx.doi.org/10.1007/s10549-005-9042-6
35. HUGHES S, AGBAJE O, BOWEN RL, HOLLIDAY DL, SHAW JA et al. Matrix metalloproteinase single-nucleotide polymorphisms and haplotypes predict breast cancer progression. Clin Cancer Res 2007; 13: 6673-6680. http://dx.doi.org/10.1158/1078-0432.CCR-07-0884
36. PRICE SJ, GREAVES DR, WATKINS H Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene-Role of Sp1 in allele-specific transcriptional regulation. J Biol Chem 2001; 276: 7549-7558. http://dx.doi.org/10.1074/jbc.M010242200
37. GRIEU F, LI WQ, IACOPETTA B Genetic polymorphisms in the MMP-2 and MMP-9 genes and breast cancer phenotype. Breast Cancer Res Treat 2004; 88: 197-204. http://dx.doi.org/10.1007/s10549-004-0595-6
38. ZHOU YF, YU CY, MIAO XP, TAN W, LIANG G et al. Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. Carcinogenesis 2004; 25: 399-404.
39. BEEGHLY-FADIEL A, LU W, LONG JR, SHU XO, ZHENG Y et al. Matrix Metalloproteinase-2 Polymorphisms and Breast Cancer Susceptibility. Cancer Epidemiol Biomarkers Prev 2009; 18: 1770-1776. http://dx.doi.org/10.1158/1055-9965.EPI-09-0125
40. DELGADO-ENCISO I, CEPEDA-LOPEZ FR, MONRROYGUIZAR EA, BAUTISTA-LAM JR, ANDRADE-SOTO M et al. Matrix metalloproteinase-2 promoter polymorphism is associated with breast cancer in a Mexican population. Gynecol Obstet Invest 2008; 65: 68-72. http://dx.doi.org/10.1159/000108282
41. ROEHE AV, FRAZZON APG, AGNES G, DAMIN AP, HARTMAN AA et al. Detection of polymorphisms in the promoters of matrix metalloproteinases 2 and 9 genes in breast cancer in South Brazil: preliminary results. Breast Cancer Res Treat 2007; 102: 123-124. http://dx.doi.org/10.1007/s10549-006-9273-1
42. KRIPPL P, LANGSENLEHNER U, RENNER W, YAZDANIBIUKI B, KOPPEL H et al. The 5A/6A polymorphism of the matrix metalloproteinase 3 gene promoter and breast cancer. Clin Cancer Res 2004; 10: 3518-3520. http://dx.doi.org/10.1158/1078-0432.CCR-04-0010
43. LEI HX, ZALOUDIK J, VORECHOVSKY I Lack of association of the-1171 (5A) allele of the MMP3 promoter with breast cancer. Clin Chem 2002; 48: 798-799.
44. BEEGHLY-FADIEL A, SHU XO, LONG JR, LI C, CAI QY et al. Genetic polymorphisms in the MMP-7 gene and breast cancer survival. Int J Cancer 2009; 124: 208-2014. http://dx.doi.org/10.1002/ijc.23859
45. ZHANG JH, JIN X, FANG SM, WANG R, LI Y et al. The functional polymorphism in the matrix metalloproteinase-7 promoter increases susceptibility to esophageal squamous cell carcinoma, gastric cardiac adenocarcinoma and non-small cell lung carcinoma. Carcinogenesis 2005; 26: 1748-1753. http://dx.doi.org/10.1093/carcin/bgi144
46. BEEGHLY-FADIEL A, LONG JR, GAO YT, LI C, QU SM et al. Common MMP-7 polymorphisms and breast cancer susceptibility: A multistage study of association and functionality. Cancer Res 2008; 68: 6453-6459. http://dx.doi.org/10.1158/0008-5472.CAN-08-0636
47. BALBIN M, FUEYO A, TESTER AM, PENDAS AM, PITIOT AS et al. Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet 2003; 35: 252-257. http://dx.doi.org/10.1038/ng1249
48. MONTEL V, KLEEMAN J, AGARWAL D, SPINELLA D, KAWAI K et al. Altered metastatic behavior of human breast cancer cells after experimental manipulation of matrix metalloproteinase 8 gene expression. Cancer Res 2004; 64: 1687-1694. http://dx.doi.org/10.1158/0008-5472.CAN-03-2047
49. WANG H, PARRY S, MACONES G, SAMMEL MD, FERRAND PE et al. Functionally significant SNP MMP8 promoter haplotypes and preterm premature rupture of membranes (PPROM). Hum Mol Genet 2004; 13: 2659-2669. http://dx.doi.org/10.1093/hmg/ddh287
50. DECOCK J, LONG J-R, LAXTON RC, SHU X-O, HODGKINSON C et al. Association of matrix metalloproteinase-8 gene variation with breast cancer prognosis. Cancer Res 2007; 67: 10214-21. http://dx.doi.org/10.1158/0008-5472.CAN-07-1683
51. ZHANG BP, YE S, HERRMANN SM, ERIKSSON P, DE MAAT M et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 1999; 99: 1788-1794.
52. BEEGHLY-FADIEL A, LU W, SHU XO, LONG JR, CAI QY et al. MMP9 polymorphisms and breast cancer risk: a report from the Shanghai Breast Cancer Genetics Study. Breast Cancer Res Treat 2011; 126: 507-513. http://dx.doi.org/10.1007/s10549-010-1119-1
53. JORMSJO S, YE S, MORITZ J, WALTER DH, DIMMELER S et al. Allele-specific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. Circ Res 2000; 86: 998-1003.
54. SHIN AS, CAI QY, SHU XO, GAO YT, ZHENG W Genetic polymorphisms in the matrix metalloproteinase 12 gene (MMP12) and breast cancer risk and survival: the Shanghai Breast Cancer Study. Breast Cancer Res 2005; 7: R506-R512. http://dx.doi.org/10.1186/bcr1033
55. MARCHENKO GN, MARCHENKO ND, STRONGIN AY The structure and regulation of the human and mouse matrix metalloproteinase-21 gene and protein. Biochem J 2003; 372: 503-515. http://dx.doi.org/10.1042/BJ20030174
56. SHAGISULTANOVA EI, NOVIKOVA IA, SIDORENKO YS, MARCHENKO GN, STRONGIN AY et al. The matrix metalloproteinase-21 gene 572C/T polymorphism and the risk of breast cancer. Anticancer Res 2004; 24: 199-201.
57. PENG B, CAO LH, MA XP, WANG WZ, WANG D et al. Metaanalysis of association between matrix metalloproteinases 2, 7 and 9 promoter polymorphisms and cancer risk. Mutagenesis 2010; 25: 371-379. http://dx.doi.org/10.1093/mutage/geq015
58. PENG B, CAO LH, WANG WZ, XIAN LL, JIANG DK et al. Polymorphisms in the promoter regions of matrix metalloproteinases 1 and 3 and cancer risk: a meta-analysis of 50 case-control studies. Mutagenesis 2010; 25: 41-48. http://dx.doi.org/10.1093/mutage/gep041
59. MCCOLGAN P, SHARMA P Polymorphisms of matrix metalloproteinases 1, 2, 3 and 9 and susceptibility to lung, breast and colorectal cancer in over 30,000 subjects. Int J Cancer 2009; 125: 1473-1478. http://dx.doi.org/10.1002/ijc.24441
60. ZHOU P, DU LF, LV GQ, YU XM, GU YL et al. Current evidence on the relationship between four polymorphisms in the matrix metalloproteinases (MMP) gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2011; 127: 813-818. http://dx.doi.org/10.1007/s10549-010-1294-0
61. HE T No evidence indicated that polymorphisms of the matrix metalloproteinases genes were associated with breast cancer risk: an update. Breast Cancer Res Treat 2011, 128: 589-59. http://dx.doi.org/10.1007/s10549-011-1406-5
62. WU XY, CHEN MB, WANG LQ, XU Y, TAN Y et al. Polymorphisms of matrix metalloproteinases (MMP) gene and breast cancer risk: appraisal of a recent meta-analysis. Breast Cancer Res Treat 2011, 130: 357-358. http://dx.doi.org/10.1007/s10549-011-1617-9
63. MAVADDAT N, ANTONIOU AC, EASTON DF, GARCIA-CLOSAS M. Genetic susceptibility to breast cancer. Mol Oncol 2010, 4: 174-191. http://dx.doi.org/10.1016/j.molonc.2010.04.011